Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 12/20 | 0.56 |
| ▸ | ABL1 | P00519 | 7/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 3/20 | 0.43 |
| ▸ | YES1 | P07947 | 2/20 | 0.43 |
| ▸ | GHSR | Q92847 | 1/20 | 0.43 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 2/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5996827 | 0.93 | SRC (0.54) | SRCABL1PDGFRBALDH1A1LMNA | |
| SCHEMBL5995422 | 0.92 | ABL1 (0.53) | SRCABL1PDGFRBALDH1A1LMNA | |
| SCHEMBL5997659 | 0.90 | SRC (0.48) | SRCABL1PDGFRBALDH1A1LMNA | |
| SCHEMBL5996220 | 0.86 | SRC (0.56) | SRCABL1PDGFRBALDH1A1LMNA | |
| SCHEMBL2498530 | 0.85 | CSF1R (0.51) | SRCABL1PDGFRBALDH1A1KDR | |
| SCHEMBL5997334 | 0.84 | KDR (0.48) | SRCABL1PDGFRBKDRLCK | |
| SCHEMBL5998026 | 0.84 | LCK (0.57) | SRCABL1PDGFRBLMNAGHSR | |
| SCHEMBL2495540 | 0.84 | BTK (0.61) | SRCABL1PDGFRBKDREPHB4 | |
| SCHEMBL5998182 | 0.83 | SRC (0.56) | SRCABL1PDGFRBGHSRLCK | |
| SCHEMBL5997190 | 0.82 | SRC (0.56) | SRCABL1PDGFRBKDM4EKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060247250-A1 | Pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247250-A1 | Pyrimidine inhibitors of kinases | DTYMK, SRC, DCK | SRC 2/4885ABL1 12/4885PDGFRB 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.